Liposome-incorporated nystatin

Details Liposome-incorporated nystatin Liposome-incorporated nystatin

1987-03-03

1989-03-14

Robinson, Douglas W.

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Biocides; animal or insect repellents or attractants

264 41, 264 43, 264 46, 424450, 4284022, 514 31, A61K 3722, A61K 3700, A61J 500, B32B 516

Patent

active

048123129

ABSTRACT:
The present invention involves a liposomal agent for treating disseminated fungal infection in an animal. This liposomal agent comprises the polyene antifungal compound nystatin. The nystatin is encapsulated within a liposome. The liposome in which the nystatin is incorporated is preferably a stable multilamellar vesicle. The liposome broadly comprises one or more lipids one or more of phosphomonoglyceride, phosphatidic acid and sphingolipid. The lipids are preferably one or more of phosphatidylcholine, phosphatidylserine, phosphatidylglycerol, sphingomyelin or phosphatidic acid. The lipids are most preferably one or more of dimyristoylphosphatidylcholine, dimyristoylphosphatidylglycerol, phosphatidylcholine and phosphatidylglycerol. The liposome of the present invention may comprise a sterol most preferably cholesterol. An important aspect of the present invention involves a method for treating disseminated fungal infection in an animal. This method comprises administering to an animal subject to disseminated fungal infection a fungicidally effective amount of nystatin encapsulated within a liposome. The liposome is composed as described above. The administering is preferably parenteral in most instances but may be oral or topical if specific colonies of fungus are thereby more directly reached. This treatment method is most useful when the animal is a human suffering from disseminated fungal infection. The method of treatment involves a fungicidally effective amount of liposome-incorporated nystatin of between about 1 mg nystatin/kg body weight and about 6 mg nystatin/kg body weight. In a most preferred embodiment the treatment method comprises liposomes consisting essentially of dimyristoylphosphatidylcholine and dimyristoylphosphatidylglycerol in a ratio of about 7:3.

REFERENCES:
patent: 4186183 (1980-01-01), Steck et al.
patent: 4235871 (1980-11-01), Papahadjopoulos et al.
patent: 4330534 (1982-05-01), Sakurai et al.
patent: 4515736 (1985-05-01), Deamer
International Search Report for PCT/US 88/00632.
Iqbal, Z. et al., Chem. Abstracts (1979), 91, No. 15:426-435.
Cohen, B. E., Chem. Abstracts (1975), 83, No. 9:267.
New, R. R. C., "Antileishmanial Activity of Amphotericin and Other Antifungal Agents Entrapped in Liposomes", Journal of Antimicrobial Chemotherapy, 1981, pp. 371-381.
Tom, Baldwin, H., "An Overview: Liposomes and Immunobiology-Macrophages, Liposomes, and Tailored Immunity", 1980, Liposomes and Immunobiology, pp. 3-19.
The Merck Index, 10th Edition, Martha Windholz (ed.), Merck & Co., Inc., Rahway, N.J. (1983), p. 85, section 611.
The Merck Index, 10th Edition, Martha Windholz (ed.), Merck & Co., Inc., Rahway, N.J. (1983), p. 967, section 6580.
LEXIS/NEXIS Patent Search.
DIALOG Literature Search.
Chemical Abstracts, vol. 91, 1979, 102345n, p. 80.
Chemical Abstracts, vol. 92, 1980, 123748q, pp. 248-249.
Chemical Abstracts, vol. 92, 1980, 176122e, p. 208.
Chemical Abstracts, vol. 93, 1980, 127554j, p. 234.
Chemical Abstracts, vol. 95, 1981, 161822w, p. 33.
Chemical Abstracts, vol. 96, 1982, 57652a, p. 360.
Chemical Abstracts, vol. 84, 1976, 146551m, p. 205.
Chemical Abstracts, vol. 87, 1977, 80067m, p. 193.
Chemical Abstracts, vol. 87, 1977, 193716r, p. 40.
Chemical Abstracts, vol. 91, 1979, 104067x, p. 251.
Chemical Abstracts, vol. 93, 1980, 142742n, p. 32.
Chemical Abstracts, vol. 93, 1980, 198021u, p. 85.
Chemical Abstracts, vol. 93, 1980, 198503c, p. 141.
Chemical Abstracts, vol. 95, 1981, 37636z, p. 272.
Chemical Abstracts, vol. 95, 1981, 182480y, p. 219.
Chemical Abstracts, vol. 87, 1977, 195913b, p. 254.
Chemical Abstracts, vol. 89, 1978, 157215j, p. 23.
Chemical Abstracts, vol. 90, 1979, 163615b, p. 179.
Chemical Abstracts, vol. 90, 1979, 82569n, p. 206.
Abstracts of the 1983 ICAAC, p. 133.
Product Information, p. 1929, Physician's Desk Reference.
Chemical Abstracts, vol. 78, 1973, 53407e, pp. 106-107.
Chemical Abstracts, vol. 79, 1973, 27977s, p. 108.
Chemical Abstracts, vol. 79, 1973, 28102q, p. 119.
Chemical Abstracts, vol. 80, 1974, 23178e, pp. 80-81.
Chemical Abstracts, vol. 84, 1976, 100974y, p. 185.
Chemical Abstracts, vol. 87, 1977, 163184y, p. 177.
Magee, Wayne E. et al., "A Comparison of Negatively and Positively Charged Liposomes Containing Entrapped Polyinosinic Polycytidylic Acid for Interferon Induction in Mice", 451, Biochimica et Biophysica Acta, 1976, pp. 610-618.
Abstracts of the 1982 ICAAC, p. 152.
Abstracts of the 1983 ICAAC, p. 222.
Schassner et al., Biochemical Pharmacology, 35:4110-4113 (1986).
Lopez-Berestein, G. et al., "Effects of Sterols on the Therapeutic Efficacy of Liposomal Amphotericin B in Murine Candidiasis", vol. 1, No. 1, Cancer Drug Delivery, 1983, pp. 37-42.
Lopez-Berestein, G. et al., "Treatment and Prophylaxis of Disseminated Infection Due to Candida Albicans in Mice with Liposome-Encapsulated Amphotericin B", vol. 147, No. 5, The Journal of Infectious Diseases, May 1983, pp. 939-945.
Juliano, Rudy et al., "Pharmacokinetic and Therapeutic Consequences of Liposomal Drug Delivery: Fluorodeoxyuridine and Amphotericin B as Examples", vol. 47, Biologie Cellularaire, May 1983, pp. 39-46.
Hopfer

Affiliated with

Also associated with

Rating

Liposome-incorporated nystatin does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Liposome-incorporated nystatin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Liposome-incorporated nystatin will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-892868